The firm will use the funds to establish a commercial lab and continue advancing its AI- and sequencing-based platform for personalizing cancer treatment.

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

The firm is using immunohistochemistry to gauge biomarker expression before enrolling patients in a trial of its CLDN 18.2-directed antibody-drug conjugate.

In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

A new study found that fewer African and Asian patients had clinically actionable alterations for lung, breast, and colorectal cancer.

The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.